AWS HealthOmics customers

"Using AWS HealthOmics, we can further our understanding of biology, target, and disease, ultimately informing decisions in Research and Development. For a company of Amgen’s size, having everything in one place is tremendous for reproducibility, transparency, security, and permissions."

Ittai Eres, Senior Scientist in Bioinformatics Technologies, Center for Research Acceleration by Digital Innovation, Amgen

“Caris Life Sciences is transforming cancer care by combining
our precision medicine expertise with the secure, scalable
workflows from AWS HealthOmics. With these capabilities,
we’re unlocking new possibilities in data-driven oncology to
deliver faster, more innovative, and more personalized patient solutions.”

David Spetzler, President, Caris Life Sciences

“With AWS HealthOmics, we moved from fragmented, hard‑to‑maintain workflows to a unified, event‑driven bioinformatics architecture. HealthOmics manages the heavy lifting of compute orchestration and observability, so our engineers can iterate quickly on pipelines, control per‑sample costs, and confidently scale cancer testing across our portfolio.“

Antonio Rueda​, Sr. Director, Bioinformatics Engineering, Abbott Cancer Diagnostics

Read the blog

“Inocras's genomic analysis system infrastructure has
evolved through three major phases: On-premises, Cloud
migration, and Cloud native. The volume of incoming orders
exceeded our expectations, resulting in demands for
computing power and storage that surpassed our internal
projections. With HealthOmics, infrastructure is
implemented according to the computing resources defined in the workflow without building infrastructure in advance.”

Dawoon Jung, Solutions Architect and DevOps, Inocras

"In drug discovery research, integrated analysis combining genomic data and other omics-related biological information is essential for identifying drug targets. The linkage between genomics-informed precision medicine and drug discovery is also becoming increasingly important. In 2023, Eisai validated AWS HealthOmics and confirmed the effectiveness of integrating omic analysis with AWS services for drug discovery research. We are pleased that with the launch of AWS HealthOmics in the Tokyo Region, we can accelerate drug discovery innovation using a global-standard genomic analysis servicewhile meeting domestic data residency requirements."

Kentaro Takahashi, Executive Director of Human Biology
Data Ecosystem, Integrated Data Science, Human Biology Creation Hub at Eisai Co., Ltd.

"Prior to AWS HealthOmics, running a bioinformatics pipeline required engaging individual bioinformaticians using their own tools and methods, resulting in inconsistentworkflows and communication silos. This integration has reduced the number of manual steps and dependencies required to run analyses, improving efficiency and allowing teams to move more quickly from data to insight."

Alexander Falk, Bioinformatics Director, Kite Pharma, a Gilead Company

"With the pipeline we've built using Amazon Bedrock,
Amazon SageMaker UI, and AWS HealthOmics, we see
potential to accelerate the time to insights from months to
minutes—to enable our researchers to quickly make
informed decisions to find the best path forward for tests in development.”

Mirko Buholzer, VP of Software Engineering, Natera

"Climate change isn't giving agriculture the luxury of time.
While we could develop resilient traits through conventional
breeding, it might take decades we don't have. We need to
process thousands of multimodal omics experiments,
something that would have been impossible with our
on-premises infrastructure. AWS HealthOmics transformed
how we approach bioinformatics at scale. We can deploy our
customized nf-core pipelines across thousands of datasets
while the service handles all the resource scaling and parallelization automatically.”

David Spetzler, President, Caris Life Sciences
Dr. Nicolas Kral, CTO and Co-founder, Phytoform Labs

"Our bioinformaticians no longer need hand-holding. For
example, we use AWS HealthOmics to cut the time to
complete analysis for cancer research from 1 year to 3 months. That’s the value that we’re getting right now."

Victor Sankarlingam, Senior Infrastructure Architect at Roche

"At Children’s Hospital of Philadelphia, we know that getting
a comprehensive view of our patients is crucial to delivering
the best possible care, based on the most innovative
research. Combining multiple clinical modalities is
foundational to achieving this. With AWS HealthOmics, we
can expand our understanding of our patients’ health, all the way down to their DNA."

Jeff Pennington, Associate Vice President, Chief Research Informatics Officer, The Children’s Hospital of Philadelphia

"In C2i Genomics, we empower our data scientists by providing them cloud-based computational solutions to run high-scale, customizable genomic pipelines, allowing them to focus on method development and clinical performance, while the company’s engineering teams are responsible for the operations, security, and privacy aspects of the workloads. AWS HealthOmics allows researchers to use tools and languages from their own domain and considerably reduces the engineering maintenance effort while taking care of cost and resource allocation considerations, which, in turn, reduce time-to-market and NRE costs of new features and algorithmic improvements."

Ury Alon, VP of Engineering, C2i Genomics

"Ultima Genomics is unleashing the power of genomics at scale. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. We are excited to work with AWS to help our customers to scale secondary analysis with AWS HealthOmics."

Omer Barad, VP of Genomic Solutions, Ultima Genomics

“Large-scale datasets need to be processed efficiently. Using AWS HealthOmics accelerates data processing and supports our use of AI, especially as we look at gene expression at the cellular level."

Dr. Joon-Yong AnAssociate Professor, School of Biosystem and Biomedical Science, Korea University College of Health Science

"At Sentieon, we are dedicated to enabling precision data for
precision medicine. AWS HealthOmics simplifies the
infrastructure setup to run Sentieon’s suite of bioinformatics
secondary analysis tools. We look forward to offering our analysis workflows on AWS HealthOmics."

Brendan Gallagher, Head of Business Development, Sentieon

BioTeam is a life sciences IT consulting company assionate about accelerating scientific discovery by closing the gap between what scientists want to do with data and what they can do.

"We look forward to utilizing AWS HealthOmics as one of
our tools to help simplify automating the collection,
organization, and transformation of data from large genomic
sequencing efforts for our clients."

William Van Etten, Co-founder and Senior Scientific Consultant, BioTeam

"At Lifebit, we’re on a mission to connect the world’s biomedical data to obtain novel therapeutic insights. Our customers work with vast cohorts of linked genomic, multi-omics and clinical data - and these data volumes are expanding rapidly. With AWS HealthOmics they will have access to optimised analytics and storage for this large-scale data, allowing us to provide even more scalable bioinformatics solutions. Our customers will benefit from significantly lower cost per gigabase of data, essentially achieving hot storage performance at cold storage prices, removing cost as a barrier to generating insights from their population-scale biomedical data."

Thorben Seeger, Chief Business Development Officer, Lifebit

"With AWS HealthOmics, we are able to provide biotech and pharma companies with advanced analytics to accelerate drug discovery and cut research study timelines by 70%."

Dr. Matthew Alderdice, Head of Data Science at Sonrai